Table 1:
Patient demographics, cancer and treatment details for all patients with ICI myocarditis and patients with abnormal versus normal T1 values.
| With T1 mapping‡ | Abnormal T1 values* | Normal T1 values | ||
|---|---|---|---|---|
| (N=86) | (N=67) | (N=19) | p† | |
| Age at start of ICI, years | 66.3±13.1 | 66.4±12.9 | 65.7±14.2 | 0.84 |
| Female | 28 (32.6) | 17 (25.4) | 11 (57.9) | 0.012 |
| CV risk factors | ||||
| • Hypertension | 47 (56.0) | 36 (54.6) | 11 (61.1) | 0.79 |
| • Diabetes mellitus | 15 (19.0) | 9 (15.0) | 0.18 | |
| • No CV risk factors | 23 (26.7) | 20 (30.0) | 3 (15.8) | 0.073 |
| Prior coronary artery disease | 11 (14.3) | 6 (10.2) | 5 (27.8) | 0.12 |
| Prior stroke | 3 (3.9) | 2 (3.3) | 1 (5.6) | 0.55 |
| Prior heart failure | 1 (1.3) | 1 (1.7) | 0 (0.0) | 1.00 |
| Chronic kidney disease | 4 (5.9) | 4 (7.7) | 0 (0.0) | 0.24 |
| Body mass index, kg/m2 | 27.8±6.3 | 27.2±6.3 | 29.4±6.3 | 0.20 |
| Primary cancer type | ||||
| Head and neck | 3 (3.5) | 1 (1.5) | 2 (10.5) | 0.12 |
| Breast | 4 (4.7) | 4 (6.0) | 0 (0.0) | 0.57 |
| Hodgkin’s lymphoma | 1 (1.2) | 1 (1.5) | 0 (0.0) | 1.00 |
| Melanoma | 37 (43.0) | 30 (44.8) | 7 (36.8) | 0.61 |
| Non-small cell lung cancer | 11 (12.8) | 8 (11.9) | 3 (15.8) | 0.70 |
| Pancreatic | 1 (1.2) | 1 (1.5) | 0 (0.0) | 1.00 |
| Renal cell carcinoma | 6 (7.0) | 6 (9.0) | 0 (0.0) | 0.33 |
| Glioblastoma | 1 (1.2) | 1 (1.5) | 0 (0.0) | 1.00 |
| Other | 22 (25.6) | 15 (22.4) | 7 (36.8) | 0.52 |
| Prior chemotherapy or radiation | ||||
| Radiation | 23 (26.7) | 15 (22.4) | 8 (42.1) | 0.14 |
| Anthracyclines | 8 (9.3) | 7 (10.5) | 1 (5.3) | 0.68 |
| ICI regimen | ||||
| Monotherapy | 58 (67.4) | 45 (67.2) | 13 (68.4) | 1.00 |
| • anti-PDl | 51 (59.3) | 38 (56.7) | 13 (68.4) | 0.43 |
| • anti-CTLA4 | 6 (7.0) | 6 (9.0) | 0 (0.0) | 0.33 |
| • anti-PDLl | 1 (12) | 1 (15) | 0 (0.0) | 1.00 |
| Dual therapy | 28 (32.6) | 22 (32.8) | 6 (31.6) | 0.49 |
Values are mean ± SD or n (%)
Percentages are represented as percentage of available data.
Abnormal T1 values were defined as values >2 standard deviation above the site, CMR vendor/field strength specific reference ranges.
Comparison between patients with normal versus abnormal T1 values was performed using the Student’s t-tests or Wilcoxon Rank Sum tests for continuous variables, as appropriate based on their normality and the Chi-squared test for categorical variables. Anti-CTLA4 = anti-cytotoxic T-lymphocyte-associated protein 4; anti-PD1 = anti-programmed cell death protein 1; anti-PDL1 = anti-programmed death-ligand 1; CMR = cardiovascular magnetic resonance; CV = cardiovascular; ICI = immune checkpoint inhibitors.